IP Library Granted Patent US 10,806,777
Granted Patent B2
US 10,806,777 · App. 15/691,395 · Granted Oct 20, 2020

Method for allogeneic cell therapy

Inventor: Michael Har-Noy (Jerusalem, IL)
Assignee: MIRROR BIOLOGICS, INC.
A61K39/0005A61K35/17C12N5/0636A61K2039/5154A61K2039/57C12N2501/51C12N2501/515C12N2531/00C12N2533/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,806,777
App. No.
15/691,395
Granted
Oct 20, 2020
Kind
B2
Abstract

A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect The anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in a patient.

Claims (6)

1. A method for stimulating a coupled host vs. tumor and host vs. graft effect in a host which mirrors the coupled graft vs. tumor and graft vs. host effects of allogeneic transplant procedures comprising:

selecting a composition of donor allogeneic cells, wherein the composition of allogeneic cells include T-cells and wherein the T-cells are activated by cross-linking of CD3 and CD28 surface antigens; and

administering said allogeneic cells to the host who has not been pre-conditioned with immunosuppressive treatment.

2. The method of claim 1 wherein the T-cells are predominately CD4+ T-cells.

3. The method of claim 2 wherein the CD4+ T-cells are predominantly Th1 cells.

4. The method of claim 1 wherein the T-cells are activated at the time of infusion.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ADDRESS OS THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 050489 FRAME: 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 28, 2020
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 052915/0513 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME FROM IMMUNOVATIVE THERAPIES, LTD. TO MICHAEL HAR-NOY ON THE ORIGINAL COVER SHEET PREVIOUSLY RECORDED ON REEL 050489 FRAME 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 2, 2019
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050610/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: IMMUNOVATIVE THERAPIES, LTD.
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050489/0245 →
RESCISSION Recorded Sep 12, 2019
From: HAR-NOY, MICHAEL
To: HAR-NOY, MICHAEL
Reel/Frame 050467/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2017
From: HAR-NOY, MICHAEL
To: IMMUNOVATIVE THERAPIES, LTD.
Reel/Frame 043683/0614 →
Continuity (11)
Division 15041642 · Feb 11, 2016
Division 14173494 · Feb 5, 2014
Division 13596142 · Aug 28, 2012
Division 12869490 · Aug 26, 2010
Continuation 12172594 · Jul 14, 2008
Division 10838454 · May 4, 2004
Provisional Application 60549032 · Mar 1, 2004
Provisional Application 60547966 · Feb 26, 2004
Provisional Application 60545450 · Feb 18, 2004
Provisional Application 60470171 · May 13, 2003
Related Publication 20170360909A1 · Dec 21, 2017